Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$37.3MCash on Hand
19.9mo Cash Runway
Follow ATHE by emailGet an email when ATHE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ATHE, unsubscribe in one click. Privacy
📣 What ATHE Says Is Next
by year-end 2026 · “Pivotal Phase 3 trial activities on track to initiate by year-end 2026”
Company press release, Jul 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Alterity Therapeutics' CEO David Stamler will present at the virtual Bell Potter Healthcare Conference on November 19, 2026 at 12:00 p.m. AEDT, with an archived webcast to follow on the company's website. Form 6-K · SEC filing · Press release
Oct 30, 2026 ·
Regulatory Alterity reported A$41.3 million cash at 30 September 2026 after about A$5.5 million from ATHO option exercises and a A$3.98 million R&D tax refund. FDA End-of-Phase 2 minutes confirmed a Phase 3 design for ATH434 in MSA, with about 200 patients randomized 1:1 for 12 months. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Financing Alterity Therapeutics furnished Exhibit 99.1, a proposed issue of securities, with the offering terms not included in the text provided. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
Shareholder vote Alterity Therapeutics furnished a Notice of Annual General Meeting and Proxy Form as Exhibit 99.1. The filing text itself contains no financial or operational results. Form 6-K · SEC filing · Press release
Oct 19, 2026 ·
Alterity Therapeutics' CEO David Stamler will take part in a fireside chat at the Craig-Hallum Virtual Biotech Catalyst Conference on October 22, 2026, at 2:30 p.m. ET, with an archived webcast to follow. Form 6-K · SEC filing · Press release
Oct 9, 2026 ·
Alterity CEO David Stamler will present a corporate presentation and host investor roundtables at the Canaccord Genuity Drug and Device Conference on October 12, 2026, at 3:50 p.m. AEST. No new data disclosed. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Clinical trial Alterity presented new analyses of its ATH434 Phase 2 trial in MSA. After adjusting for baseline CSF NfL, the 50 mg dose slowed functional decline on the 11-item UMSARS Part I by a -4.64-point difference versus placebo at Week 52 (p=0.032), roughly 52% slowing. Form 6-K · SEC filing · Press release
Sep 25, 2026 ·
Shareholder vote Alterity Therapeutics will hold its next annual general meeting at 11.00am (AEDT) on Friday 20 November 2026. Director nominations must be received in writing by 5.00pm (AEST) on Friday 2 October 2026. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2029 · Phase 2 · Enrolling · Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ATHE holds $37.3M in cash and short-term investments and burns about $5.6M/quarter from operations,
an estimated runway of 19.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:8 · Low
Cash runway 20 months +8
Recent financing filings on SEC EDGAR:
Feb 15, 2024 · Registered direct / best-efforts offering · 424B5
Share count 217,508,862 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ATHE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATHE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.